PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

INTRODUCTION: BAY 94‐9027, a site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII) with extended half‐life, demonstrated efficacy for bleed prevention and treatment in previously treated adolescents and adults with severe haemophilia A. AIM: To assess BAY 94‐9027 in children...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haemophilia
Main Authors: Santagostino, Elena, Kenet, Gili, Fischer, Kathelijn, Biss, Tina, Ahuja, Sanjay, Steele, MacGregor, Martínez, M., Male, C., van Geet, C., Mondelaers, V., Kaleva, V., Stoyanova‐Deleva, A., Bobev, D., Blanchette, V., Zanon, E., Gagliano, F., Rageliene, L., Peters, M., Mlynarski, W., Badowska, W., Serban, M., Rusen, L., Uscatescu, V., Will, A., Payne, J., Tunstall, O., Kerlin, B., Gruppo, R., Eyster, M. E., Ducore, J., Schwartz, J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317355/
https://ncbi.nlm.nih.gov/pubmed/32212300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados